Compare ARK Genomic Revolution ETF (ARKG) vs Rockwell Automation (ROK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Rockwell Automation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Rockwell Automation trades at $470.46 (market cap $52.53B). The key difference: Rockwell Automation pays a 1.17% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | ROK | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $495.08 |
52-Week Low | $23.09 | $328.67 |
Market Cap | — | $52.53B |
Enterprise Value | — | $56.17B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Rockwell Automation (ROK) trades at $472.12, up 0.99% on the day, showing strong momentum with three consecutive earnings beats. The stock's technical picture is neutral with bullish moving averages, while valuation multiples remain elevated with a P/E of 49.03. Recent news highlights the company's leadership in industrial automation and AI infrastructure growth potential, with multiple Zacks recognition as a top momentum and growth stock in July 2026.
ROK presents a mixed outlook with strong operational cash flow and recent earnings outperformance offset by premium valuations. Investment opportunity lies in industrial automation growth and AI infrastructure tailwinds, while risks include competitive pressures and sensitivity to industrial spending cycles. Analyst consensus leans cautious with 64% hold ratings despite recent positive coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
